Press Release

PhRMA Statement: Drug Quality and Security Act

PhRMA November 18, 2013

Washington, D.C. (November 18, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J Castellani issued the following statement:

“PhRMA is pleased that the Senate has passed the Drug Quality and Security Act and that the bill will now head to the White House for President Obama’s signature.

“The counterfeiting of prescription drugs is on the rise within the United States but oftentimes goes unnoticed or unreported, leaving many Americans unaware of this problem. In fact, some experts have cited the counterfeiting of these medicines as even more lucrative than the trafficking of illegal drugs like heroin and cocaine.

“This Act will improve the security of the finished drug supply chain and reduce the impact of the patchwork of state laws related to the pedigree requirements for drug distribution.

“We want to commend the members of the Senate and House, especially Senate Chairman Harkin and Ranking Member Alexander  and House Chairman Upton and Ranking Member Waxman, who have worked so hard over the last two years to ensure that the prescription drug supply chain in the United States remains the safest in the world.

“We look forward to working with the FDA to appropriately implement this Act, which will foster the strong level of protection for pharmaceuticals that our citizens have come to expect.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit